Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
54868-5260-02 54868-5260 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jun 28, 2005 In Use
54868-5260-03 54868-5260 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jun 28, 2005 In Use
00004-1100-75 00004-1100 Capecitabine Xeloda 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Apr 30, 1998 Dec 31, 2014 In Use
00004-1101-51 00004-1101 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Mar 5, 2010 Dec 20, 2011 In Use
54868-4143-00 54868-4143 Capecitabine Xeloda 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb 20, 2005 In Use
00004-1100-20 00004-1100 Capecitabine Xeloda 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Apr 30, 1998 In Use
54868-5260-05 54868-5260 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jun 28, 2005 In Use
53808-0411-01 53808-0411 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jul 1, 2009 In Use
54868-5260-00 54868-5260 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jun 28, 2005 In Use
54868-5260-01 54868-5260 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jun 28, 2005 In Use
52652-2001-06 52652-2001 Methotrexate Xatmep 2.5 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Oral Aug 13, 2018 In Use
52652-2001-01 52652-2001 Methotrexate Xatmep 2.5 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Oral May 1, 2017 In Use
00069-0507-60 00069-0507 CRIZOTINIB Xalkori 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, HGFR, ROS1, RON Oral Nov 20, 2023 In Use
00069-1500-60 00069-1500 CRIZOTINIB Xalkori 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, HGFR, ROS1, RON Oral Nov 20, 2023 In Use
00069-8140-20 00069-8140 Crizotinib Xalkori 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Aug 26, 2011 In Use
00069-0251-60 00069-0251 CRIZOTINIB Xalkori 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, HGFR, ROS1, RON Oral Nov 20, 2023 In Use
00069-8141-20 00069-8141 Crizotinib Xalkori 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Aug 26, 2011 In Use
00006-5331-59 00006-5331 Belzutifan WELIREG 40.0 mg/1 Chemotherapy Miscellaneous Agent HIF-2 alpha Oral Jun 21, 2023 In Use
00006-5331-01 00006-5331 Belzutifan WELIREG 40.0 mg/1 Chemotherapy Miscellaneous Agent HIF-2 alpha Oral Aug 13, 2021 In Use
00006-5331-58 00006-5331 Belzutifan WELIREG 40.0 mg/1 Chemotherapy Miscellaneous Agent HIF-2 alpha Oral Jun 21, 2023 In Use
68727-0745-01 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug 3, 2017 In Use
68727-0745-02 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug 3, 2017 In Use
68727-0745-05 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug 3, 2017 In Use
00469-3425-10 00469-3425 ZOLBETUXIMAB VYLOY 20.0 mg/mL Immunotherapy Monoclonal Antibody CLDN18.2 Intravenous Jan 1, 2024 In Use
00173-0804-61 00173-0804 Pazopanib Hydrochloride Votrient 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, Lck, FMS Oral Oct 19, 2009 Nov 30, 2017 No Longer Used

Found 11120 results — Export these results